# A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis

> **NCT07632976** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Lanyi Therapeutics Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Antiphospholipid Syndrome (APS)
- Thrombosis

## Interventions

- **BIOLOGICAL:** EA5
- **BIOLOGICAL:** EA5

## Key facts

- **NCT ID:** NCT07632976
- **Lead sponsor:** Shanghai Lanyi Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-05-25
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07632976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07632976, "A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07632976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*